Predicting the Cost and Pace of Pharmacogenomic Advances: An Evidence-Based Study | Zendy

Ramy Arnaout | Zendy; Thomas P. Buck | Zendy; Paulvalery Roulette | Zendy; Vikas P. Sukhatme | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting the Cost and Pace of Pharmacogenomic Advances: An Evidence-Based Study

Author(s) -

Ramy Arnaout,

Thomas P. Buck,

Paulvalery Roulette,

Vikas P. Sukhatme

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.199455

Subject(s) - pharmacogenomics , adverse effect , investment (military) , dosing , medicine , actuarial science , risk analysis (engineering) , intensive care medicine , business , pharmacology , politics , political science , law

Adverse outcomes associated with prescription drug use are common and costly. Many adverse outcomes can be avoided through pharmacogenomics: choosing and dosing of existing drugs according to a person's genomic variants. Finding and validating associations between outcomes and genomic variants and developing guidelines for avoiding drug-related adverse outcomes will require further research; however, no data-driven estimates yet exist for the time or money required for completing this research.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research